

In-Vitro Activity of Teicoplanin against Clinical Methicillin Resistant *Staphylococcus aureus* Isolates

Ravi T¹, Deepak K^{1,2*}, Nayak J¹, Manish Kumar P² and Prakash V²

¹Department of Applied Microbiology, Banaras Hindu University, India

²Department of Microbiology, Banaras Hindu University, India

Research Article

Volume 2 Issue 1

Received Date: February 08, 2017

Published Date: March 02, 2017

***Corresponding author:** Dr. Deepak Kumar, Assistant Professor, Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, India, Tel: +91-9451354332; E-mail: deepak.mln30@gmail.com

Abstract

Aim: To evaluate the *in vitro* activity of teicoplanin against clinical methicillin resistant *Staphylococcus aureus* isolates was the aim of this study

Methods and Material: A total of 62 previously confirmed MRSA isolates were included in this study. Susceptibility testing and result interpretation of isolates to teicoplanin was performed by the E test and disk diffusion method as per Clinical and Laboratory Standards Institute (CLSI) M100-S25 recommendations.

Results: Teicoplanin appears to exhibit excellent *in vitro* activity against the MRSA isolates.

Conclusion: The high *in vitro* susceptibility to teicoplanin in this population and fewer adverse drug effects, teicoplanin may be considered a useful first line antibiotic agent in the treatment of infections caused by MRSA.

Keywords: Teicoplanin; MRSA; E Test; Disk Diffusion Method

Introduction

Methicillin-resistant *Staphylococcus aureus* (MRSA) are among the most prevalent pathogen responsible for hospital acquired infections [1]. MRSA infection is hard to treat as methicillin resistance in general is associated with other class of drugs like macrolides, lincosamides, aminoglycosides, quinolones, and trimethoprim-sulfamethoxazole. The treatment option for this multi-drug resistance organism is limited to glycopeptide antibiotics like vancomycin and teicoplanin. Vancomycin usage is presently a concern to clinician because of decreased efficacy despite MIC value in susceptible range [2]. Other factors restricting its use are MIC creep phenomenon and side effects like ototoxicity, and nephrotoxicity [3]. Teicoplanin on the other hand hold the promise to be a useful alternative in cases where vancomycin is clinically ineffective and in cases where use

of vancomycin is curtailed due to adverse drug affects [4,5].

Teicoplanin is a naturally occurring lipoglycopeptide that kills Gram-positive cocci by inhibiting peptidoglycan biosynthesis by binding to the D-alanyl-D-alanine termini of peptidoglycan intermediates, thus disrupting late-stage steps in cell wall biosynthesis [6]. This drug shows a great therapeutic effect to MRSA. With the constant change in the epidemiology of MRSA throughout regions and countries a variation in its drug-resistance patterns is reported [7]. Unfortunately no current resistance data from our area are available. It is thus mandatory to monitor the trends of resistance to teicoplanin in the MRSA causing infection. The aim of this study was evaluate the *in vitro* teicoplanin activity against clinical MRSA isolates.

Material and Methods

The study was carried out in the Department of Microbiology, Institute of Medical Science Banaras Hindu University, Varanasi U.P. India. The total duration of study is one year; period extends from July 2015 to June 2016. A total of 62 non-duplicate MRSA isolates from various clinical specimen like pus, blood, urine, tracheal aspirates, sputum, central venous catheters tips, CSF and other sterile body fluids were randomly selected. MRSA isolates were identified by standard microbiological techniques. Methicillin resistance was confirmed by using cephoxitin disc (30 µg Himedia labs) After isolation and identification, the MRSA strains were kept at -20°C in peptone/glycerol (30% w/v), and before teicoplanin susceptibility testing, the strains were purified twice on blood agar plates.

Susceptibility testing of the isolates to teicoplanin was performed by the disk diffusion method as per Clinical and Laboratory Standards Institute (CLSI M100-S25) [8]. The MIC values were obtained by E-test, which was performed as per manufacturer's instructions using gradient strips of teicoplanin (Biomérieux France). The disc diffusion test was performed with cation adjusted Mueller-Hinton agar (Himedia Labs) as testing media. Teicoplanin disks of content 30µg (BD USA) was used. The inoculated plates were incubated in ambient air at 37°C for 16 to 18 h. MRSA strain ATCC 43300 was used as control strains, zone of inhibition and MIC values obtained was interpreted by using CLSI M100-S25 (2015) breakpoints. The isolate was considered susceptible to teicoplanin if the zone of inhibition \geq 14mm; intermediate if zone of inhibition \leq 10mm, and intermediate if zone size is in range 11-13mm. The MIC breakpoints for teicoplanin as per CLSI was ($<$ 8 µg/ml, S; 16 µg/ml, I; $>$ 32 µg/ml, R).

Results

A total of 62 clinical MRSA isolates were included in this study. Table: 1 shows distribution of MRSA among various clinical samples. From the above table it can be said the highest number of methicillin resistant strains were obtained from pus (38.7 %) followed by blood (16.1 %) and sputum (12.9 %).

The main finding of our study is that teicoplanin exhibits excellent antimicrobial activity against MRSA isolates as none of the isolates obtained was resistant to teicoplanin. The distribution of zone of inhibition is shown in table 2. The zone size of inhibition by disc-diffusion method ranges from 14-18mm with median value of

15.7mm. Majority of the isolate (53.2 %) had zone of inhibition $>$ 16mm. The distribution of MIC values and MIC range for teicoplanin is shown in table 3. The MIC values obtained by E-test ranges from 0.38-2.00 µg/ml with a mean value of 1.00 µg/ml. For majority of isolate (69.3 %) the MIC values were $<$ 1 µg/ml. After applying the CLSI interpretative criteria all the MRSA isolates were found susceptible to teicoplanin by both the methodology. Thus a 100% concordance between the results of E-test and DD method was found.

S. no	Clinical specimens	Number of isolates (n)	Percentage (%)
1	Pus	24	38.7
2	Blood	10	16.1
3	Urine	3	4.8
4	Sputum	8	12.9
5	Tracheal aspirates	5	8.1
6	Central venous catheters tips	2	3.2
7	CSF	1	1.6
8	Other Sterile body fluids	9	14.5
	Total	62	100

Table 1: Distribution of MRSA isolates from various clinical specimens.

Zone diameter (mm)	Number(n)	Percentage (%)
$>$ 16	33	53.2
14-15	29	46.8
11-13	0	0
$<$ 10	0	0

Table 2: Distribution of zone of inhibition for teicoplanin for 62 MRSA isolates.

MIC (µg/ml)	Number(n)	Percentage (%)
$<$ 0.05	11	17.7
0.75-1.0	32	51.6
1.5-2.0	19	30.7
$>$ 4	0	0

Table 3: Distribution of MIC values for teicoplanin for 62 MRSA isolates.

Discussion

Methicillin-resistant *Staphylococcus aureus* (MRSA) is causing a wide variety of human diseases and hence increasing burden on healthcare resources. Vancomycin has been the only uniformly effective treatment for MRSA infections in India, and other glycopeptides not being

commonly used. The role of vancomycin in the treatment of MRSA has been questioned and debated due to the spread of vancomycin-intermediate *S. aureus* (VISA), and vancomycin-resistant *S. aureus* (VRSA) [9,10]. Teicoplanin, a glycopeptide class antibiotic is used intravenously or intramuscular to treat serious MRSA infections. In our study, we examined the susceptibility of teicoplanin by disc-diffusion and E-test. Few studies have reported that detection of teicoplanin resistance by conventional disc diffusion methods is difficult because of limited diffusion of its large molecule in agar [11]. This study did not find and limitations of disc susceptibility testing for MRSA with teicoplanin. Both methods provided similar results and we did not find any resistance to teicoplanin in our tested MRSA isolates.

The data presented in this study support the findings of studies performed worldwide which says that the number of MRSA resistant to teicoplanin is very low [12]. Several studies have demonstrated the relationship between teicoplanin MICs values and treatment outcome in patients with MRSA infections. A study by Charlesworth et al showed that a higher teicoplanin MIC was associated with a lower survival rate in critically ill patients [13]. The present study confirms the good in vitro activity of teicoplanin against MRSA as the mean MIC values of teicoplanin in our study was 1.00 mg/L. The high in vitro susceptibility of the isolates tested to teicoplanin and low resistance prevalence may be related to its restricted use for the treatment of MRSA infections. Teicoplanin thus, may be considered a promising treatment option for the treatment of MRSA infections in our region.

Conclusion

Based on the above results, it can be concluded that teicoplanin, is a good choice for the treatment against bacterial infections caused by methicillin resistant *Staphylococcus aureus* (MRSA). The comparative analysis demonstrates that disc-diffusion and E-test provide similar results of susceptibility. Thus, for susceptibility testing disc diffusion can be easier and economical option as compared to E test.

Acknowledgement

The authors would like to thanks Mr. Atul Kumar Awasthi area manager SANOFI for providing Teicoplanin Disc and E strips for this study.

References

1. Boyce JM, Cookson B, Christiansen K, Hori S, Vuopio VJ, et al. (2005) Methicillin-resistant *Staphylococcus aureus*. *Lancet Infect Dis* 5(10): 653-663.
2. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, et al. (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant *Staphylococcus aureus* bacteremia treated with vancomycin. *Antimicrob Agents Chemother* 52(9): 3315-3320.
3. Steinkraus G, White R, Friedrich L (2007) Vancomycin MIC creep in non vancomycin-intermediate *Staphylococcus aureus* (VISA), vancomycin susceptible clinical methicillin-resistant *S. aureus* (MRSA) blood isolates from 2001-05. *J Antimicrob Chemother* 60(4): 788-794.
4. Marinho DS, Huf G, Ferreira BL, Castro H, Rodrigues CR, et al. (2011) The study of vancomycin use and its adverse reactions associated to patients of a brazilian university hospital. *BMC Res Notes* 4: 236.
5. Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E (2010) Teicoplanin versus Vancomycin for proven or suspected infection. *Cochrane Database Syst Rev* 16(6).
6. Svetitsky S, Leibovici L, Paul M (2009) Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. *Antimicrob Agents Chemother* 53(10): 4069-4079.
7. Rodríguez NE, Seas C, Guzmán BM, Mejía C, Alvarez C, et al. (2010) Evolution of methicillin-resistant *Staphylococcus aureus* clones in Latin America. *Int J Infect Dis* 14(7): 560-566.
8. Clinical and Laboratory Standards Institute (2015) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document.
9. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, et al. (1997) Dissemination in Japanese hospitals of strains of *Staphylococcus aureus* heterogeneously resistant to vancomycin. *Lancet* 350: 1670-1673.

10. Hiramatsu K (2001) Vancomycin-resistant *Staphylococcus aureus*: a new model of antibiotic resistance. *Lancet Infect Dis* 1(3): 147-155.
11. Cavenaghi LA, Biganzoli E, Danese A, Parenti F (1992) Diffusion of teicoplanin and vancomycin in agar. *Diagn Microbiol Infect Dis* 15(3): 253-258.
12. Samra Z, Ofer O, Shmueli H (2005) Susceptibility of methicillin-resistant *Staphylococcus aureus* to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics. *Isr Med Assoc J* 7(3): 148-150.
13. Charlesworth R, Warner M, Livermore DM, Wilson AP (2006) Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant *Staphylococcus aureus*. *J Antimicrob Chemother* 58: 186-189.